The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detecting MTAP loss in liquid biopsies from patients with pancreatic ductal adenocarcinoma.
 
Camila Braganca Xavier
No Relationships to Disclose
 
Dean Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Alexa Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Richard Huang
Employment - Roche/Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Patent on IHC; provisional patent on biomarkers and biomarker methodology.
 
Ryon Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Pooja Shah
No Relationships to Disclose
 
David Fabrizio
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - 1. Novel PD-L1 binding polypeptides for imaging 2. Methods and systems for evaluating tumor mutational burden 3. Therapeutic and diagnostic methods for cancer 4. Targeted therapeutics based on engineered proteins for tyrosine kinase receptors, including
 
Jeffrey Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Tango Therapeutics
Research Funding - Foundation Medicine
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social